ALNYLAM PHARMACEUTICALS, INC. Increase (Decrease) in Restricted Cash and Investments
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Increase (Decrease) in Restricted Cash and Investments of $150.00 million for the 12-month period ending 2016-12-31, per its 10-K filed 2018-02-15.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInRestrictedCashAndInvestments · last filed 2018-02-15
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2016-12-31 was $0.00, a 100.00% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2016-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2015-12-31 was $1.18M.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for the quarter ending 2015-09-30 was $0.00.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2016 was $150.00M, a 10097.14% increase from fiscal 2015.
- ALNYLAM PHARMACEUTICALS, INC. increase (decrease) in restricted cash and investments for fiscal 2015 was $1.47M.
| Period end | Increase (Decrease) in Restricted Cash and Investments 3 month | Increase (Decrease) in Restricted Cash and Investments 6 month | Increase (Decrease) in Restricted Cash and Investments 9 month | Increase (Decrease) in Restricted Cash and Investments 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $0.00 derived: sum of 2 quarters · filed 2018-02-15 | $150.00M 10-K · filed 2018-02-15 | |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $150.00M 10-Q · filed 2017-11-07 | ||
| 2016-06-30 | $150.00M 10-Q · filed 2017-08-09 | |||
| 2015-12-31 | $1.18M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $1.18M derived: sum of 2 quarters · filed 2018-02-15 | $1.47M 10-K · filed 2018-02-15 | |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $288.00K 10-Q · filed 2016-11-03 | ||
| 2015-06-30 | $288.00K 10-Q · filed 2016-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |